Court grants preliminary approval of $15M derivative suit settlement; final hearing Aug 6

Emergent BioSolutions Inc.

Settlement covers five derivative actions alleging breach of fiduciary duty over Bayview vaccine manufacturing failures.
Insurers to pay $15M to Emergent; no admission of fault or liability by any defendant.
Board to adopt corporate governance reforms addressing manufacturing oversight and regulatory compliance.
Final approval hearing scheduled for August 6, 2025 in U.S. District Court for Maryland.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.